Glossary of terms used
apo B (apolipoprotein B), EPA (icosapent ethyl), LDL-C (Low Density Lipoprotein Cholesterol), non-HDL-C (total cholesterol less "good cholesterol"), TC (Total Cholesterol), TG (Triglycerides), VLDL-C (Very Low Density Lipoprotein Cholesterol).
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa ® (icosapent ethyl), Amarin's first FDA approved product, is a patented, ultra pure omega-3 fatty acid product comprising not less than 96% EPA and is available for use by prescription for the treatment of severe (≥500 mg/dL) hypertriglyceridemia. For more information about Vascepa visit www.vascepa.com . For more information about Amarin visit www.amarincorp.com .The Amarin Corporation plc logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13817 Forward-looking statements This press release contains forward-looking statements, including statements about the efficacy, safety and therapeutic benefits of Vascepa, clinical trial results, the clinical importance of certain biomarkers and the impact of Vascepa on such biomarkers, the timing of a commercial launch of Vascepa, and the commercial potential of Vascepa. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described herein include the following: uncertainties associated generally with the commercial success of new pharmaceutical products, such as Vascepa; and Amarin's lack of experience as a company with commercializing pharmaceutical products. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in the "Risk Factors" section of Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise except as required by law.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts